, 1997), which is an important traditional Chinese medicine used for the treatment of kidney deficiency and neurodegenerative diseases. ECH is also the main phenolic component in Echinacea angustifolia and Echinacea pallida roots (Perry et al., 2001), which are widely used in Europe, North America, and Australia for their immunostimulating activities. As a natural polyphenolic compound, ECH showed various bioactivities, such as antioxidative (Li et al., 1992;Xiong et al., 1996;Hu and Kitts, 2000;Cervellati et al., 2002), neuroprotective (Den et al., 2004;Koo et al., 2005;Chen et al., 2007;Geng et al., 2007), nitric oxide radical-scavenging (Xiong et al., 2000), and antihepatotoxic activities (Houghton and Hikino, 1989;Wu et al., 2007).Although ECH exhibited diverse bioactivities in in vivo and in vitro assays, only a few reports dealing with the metabolism and disposition of ECH are available. In our previous study on the pharmacokinetics and bioavailability of ECH in rat, the distribution and elimination of ECH were extremely fast (t 1/2␣ , 12.4 min; t 1/2 , 41.0 min), clearance was 0.0001 mg/kg/min/(ng/ml) after i.v. administration (5 mg/kg), and the bioavailability of ECH was only 0.83% (Jia et al., 2006). The very low bioavailability of ECH was consistent with the results of Matthias et al. (2004), in which ECH permeated poorly through the Caco-2 monolayers. Moreover, our pharmacokinetic data suggested that ECH was mostly metabolized after dosing. Therefore, we hypothesized that, in addition to the parent compound, some metabolic products of ECH may show biological activities, thereby contributing to the pharmacological efficacy of ECH in vivo. It was necessary to